Last reviewed 2026-04-20 · How we verify

Azilect (RASAGILINE)

Azilect (RASAGILINE) is a small molecule monoamine oxidase inhibitor (MAOI) developed by TEVA and approved by the FDA in 2006 for the treatment of Parkinson's disease. It targets the 5-hydroxytryptamine receptor 6 and has a bioavailability of 36%. Azilect is commercially available as a branded and generic medication, with multiple generic manufacturers. Key safety considerations include potential interactions with other medications and dietary restrictions. As a MAOI, Azilect can have significant effects on various neurotransmitter systems.

At a glance

Approved indications

• Parkinson's disease

Common side effects

• Hallucination
• Dyskinesia
• Impulse-control disorder
• On and off phenomenon
• Fall
• Freezing phenomenon
• Serotonin syndrome
• Hypersexuality
• Gambling disorder
• Orthostatic hypotension
• Delusion
• Bradykinesia

Drug interactions

• Alpha/Beta Agonists
• Amphetamines
• Indirectly Acting Sympathomimetic Amines
• Selective Serotonin Reuptake Inhibitors
• Serotonin/Norepinephrine Reuptake Inhibitors
• Tricyclic Antidepressants
• amitriptyline
• amoxapine
• buspirone
• ciprofloxacin
• citalopram
• clomipramine

Key clinical trials

• Effect of Rasagiline on Balance in Parkinson's Disease as Measured by Computerized Posturography (PHASE4)
• Relative Bioavailability Study of HNC364 Injectable Suspension (PHASE1)
• Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease (PHASE2,PHASE3)
• A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension (PHASE1)
• An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD
• Overnight Switch From Rasagiline To Safinamide (PHASE4)
• Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"
• Image Parkinson's Disease Progression Study (PHASE2)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.